External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home APASL 2022
Roche and Genentech at

APASL 2022

March 30 - April 03
Seoul, Korea / Virtual (Hybrid)
apasl2022seoul.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
04:30 PM
Duration 10mins Seoul, Korea - Virtual
Bevacizumab▼ and Atezolizumab▼ as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Taiwanese Subgroup Analysis
Shao YY, Feng YH, Yen CJ, Yang TS, Shen YC, Chao Y, Chen JS, Su CY, Chen WJ, Hsiang HL, Hsu CH
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.